Intravenous infusion of Hb-vesicles (artificial oxygen carriers) after repetitive blood exchange with a series of plasma expanders (water-soluble biopolymers) in a rat model

Hiromi Sakai, Norihito Miyagawa, Hirohisa Horinouchi, Shinji Takeoka, Masuhiko Takaori, Eishun Tsuchida, Koichi Kobayashi

    Research output: Contribution to journalArticle

    2 Citations (Scopus)

    Abstract

    Hemoglobin-vesicles (HbV) are artificial oxygen carriers developed for use as a transfusion alternative. The extremely high concentration of the HbV suspension (solutes, ca. 16g/dl; volume fraction, ca. 40vol%) provides a sufficient oxygen carrying capacity to maintain oxygen metabolism. A suspension of HbV has no colloid osmotic pressure (COP). Consequently, a combination of a plasma expander is necessary for a massive dose of HbV. Clinically available plasma expanders include hydroxyethyl starch (HES), modified gelatin (MFG), or recombinant human serum albumin (rHSA). Our previous studies confirmed that these water-soluble biopolymers interact with HbV to induce flocculation of HbV reversibly by depletion interaction, especially with MFG and high molecular weight HES. It remains unknown whether such flocculate formation in blood might affect animal's hemodynamics. Using a rat model, we tested infusion of a series of plasma expander to maintain the blood volume (level of blood exchange led to 60%) at repeated hemorrhages and the subsequent infusion of HbV (20ml/kg, 36% of blood volume). All rats survived for 4hr after the infusion of HbV; hemodynamic and respiratory functions were preserved, indicating that the flocculation does not induce capillary embolism. Blood exchange with rHSA and subsequent infusion of HbV showed more stable systemic parameters because of the longer retention of rHSA in blood than other plasma substitutes, indicating that rHSA is suitable for combination with HbV in this experimental model.

    Original languageEnglish
    Pages (from-to)1216-1222
    Number of pages7
    JournalPolymers for Advanced Technologies
    Volume22
    Issue number8
    DOIs
    Publication statusPublished - 2011 Aug

    Fingerprint

    Biopolymers
    Hemoglobin
    Rats
    Hemoglobins
    Blood
    Oxygen
    Plasmas
    Water
    Serum Albumin
    Hemodynamics
    Flocculation
    Gelatin
    Starch
    Suspensions
    Plasma Substitutes
    Colloids
    Metabolism
    Volume fraction
    Animals
    Molecular weight

    Keywords

    • Artificial red cells
    • Biomacromolecules
    • Blood substitutes
    • Hemoglobin
    • Liposome

    ASJC Scopus subject areas

    • Polymers and Plastics

    Cite this

    Intravenous infusion of Hb-vesicles (artificial oxygen carriers) after repetitive blood exchange with a series of plasma expanders (water-soluble biopolymers) in a rat model. / Sakai, Hiromi; Miyagawa, Norihito; Horinouchi, Hirohisa; Takeoka, Shinji; Takaori, Masuhiko; Tsuchida, Eishun; Kobayashi, Koichi.

    In: Polymers for Advanced Technologies, Vol. 22, No. 8, 08.2011, p. 1216-1222.

    Research output: Contribution to journalArticle

    Sakai, Hiromi ; Miyagawa, Norihito ; Horinouchi, Hirohisa ; Takeoka, Shinji ; Takaori, Masuhiko ; Tsuchida, Eishun ; Kobayashi, Koichi. / Intravenous infusion of Hb-vesicles (artificial oxygen carriers) after repetitive blood exchange with a series of plasma expanders (water-soluble biopolymers) in a rat model. In: Polymers for Advanced Technologies. 2011 ; Vol. 22, No. 8. pp. 1216-1222.
    @article{7c7f6b0ca3ab46faa9379ecbecce5af7,
    title = "Intravenous infusion of Hb-vesicles (artificial oxygen carriers) after repetitive blood exchange with a series of plasma expanders (water-soluble biopolymers) in a rat model",
    abstract = "Hemoglobin-vesicles (HbV) are artificial oxygen carriers developed for use as a transfusion alternative. The extremely high concentration of the HbV suspension (solutes, ca. 16g/dl; volume fraction, ca. 40vol{\%}) provides a sufficient oxygen carrying capacity to maintain oxygen metabolism. A suspension of HbV has no colloid osmotic pressure (COP). Consequently, a combination of a plasma expander is necessary for a massive dose of HbV. Clinically available plasma expanders include hydroxyethyl starch (HES), modified gelatin (MFG), or recombinant human serum albumin (rHSA). Our previous studies confirmed that these water-soluble biopolymers interact with HbV to induce flocculation of HbV reversibly by depletion interaction, especially with MFG and high molecular weight HES. It remains unknown whether such flocculate formation in blood might affect animal's hemodynamics. Using a rat model, we tested infusion of a series of plasma expander to maintain the blood volume (level of blood exchange led to 60{\%}) at repeated hemorrhages and the subsequent infusion of HbV (20ml/kg, 36{\%} of blood volume). All rats survived for 4hr after the infusion of HbV; hemodynamic and respiratory functions were preserved, indicating that the flocculation does not induce capillary embolism. Blood exchange with rHSA and subsequent infusion of HbV showed more stable systemic parameters because of the longer retention of rHSA in blood than other plasma substitutes, indicating that rHSA is suitable for combination with HbV in this experimental model.",
    keywords = "Artificial red cells, Biomacromolecules, Blood substitutes, Hemoglobin, Liposome",
    author = "Hiromi Sakai and Norihito Miyagawa and Hirohisa Horinouchi and Shinji Takeoka and Masuhiko Takaori and Eishun Tsuchida and Koichi Kobayashi",
    year = "2011",
    month = "8",
    doi = "10.1002/pat.1964",
    language = "English",
    volume = "22",
    pages = "1216--1222",
    journal = "Polymers for Advanced Technologies",
    issn = "1042-7147",
    publisher = "John Wiley and Sons Ltd",
    number = "8",

    }

    TY - JOUR

    T1 - Intravenous infusion of Hb-vesicles (artificial oxygen carriers) after repetitive blood exchange with a series of plasma expanders (water-soluble biopolymers) in a rat model

    AU - Sakai, Hiromi

    AU - Miyagawa, Norihito

    AU - Horinouchi, Hirohisa

    AU - Takeoka, Shinji

    AU - Takaori, Masuhiko

    AU - Tsuchida, Eishun

    AU - Kobayashi, Koichi

    PY - 2011/8

    Y1 - 2011/8

    N2 - Hemoglobin-vesicles (HbV) are artificial oxygen carriers developed for use as a transfusion alternative. The extremely high concentration of the HbV suspension (solutes, ca. 16g/dl; volume fraction, ca. 40vol%) provides a sufficient oxygen carrying capacity to maintain oxygen metabolism. A suspension of HbV has no colloid osmotic pressure (COP). Consequently, a combination of a plasma expander is necessary for a massive dose of HbV. Clinically available plasma expanders include hydroxyethyl starch (HES), modified gelatin (MFG), or recombinant human serum albumin (rHSA). Our previous studies confirmed that these water-soluble biopolymers interact with HbV to induce flocculation of HbV reversibly by depletion interaction, especially with MFG and high molecular weight HES. It remains unknown whether such flocculate formation in blood might affect animal's hemodynamics. Using a rat model, we tested infusion of a series of plasma expander to maintain the blood volume (level of blood exchange led to 60%) at repeated hemorrhages and the subsequent infusion of HbV (20ml/kg, 36% of blood volume). All rats survived for 4hr after the infusion of HbV; hemodynamic and respiratory functions were preserved, indicating that the flocculation does not induce capillary embolism. Blood exchange with rHSA and subsequent infusion of HbV showed more stable systemic parameters because of the longer retention of rHSA in blood than other plasma substitutes, indicating that rHSA is suitable for combination with HbV in this experimental model.

    AB - Hemoglobin-vesicles (HbV) are artificial oxygen carriers developed for use as a transfusion alternative. The extremely high concentration of the HbV suspension (solutes, ca. 16g/dl; volume fraction, ca. 40vol%) provides a sufficient oxygen carrying capacity to maintain oxygen metabolism. A suspension of HbV has no colloid osmotic pressure (COP). Consequently, a combination of a plasma expander is necessary for a massive dose of HbV. Clinically available plasma expanders include hydroxyethyl starch (HES), modified gelatin (MFG), or recombinant human serum albumin (rHSA). Our previous studies confirmed that these water-soluble biopolymers interact with HbV to induce flocculation of HbV reversibly by depletion interaction, especially with MFG and high molecular weight HES. It remains unknown whether such flocculate formation in blood might affect animal's hemodynamics. Using a rat model, we tested infusion of a series of plasma expander to maintain the blood volume (level of blood exchange led to 60%) at repeated hemorrhages and the subsequent infusion of HbV (20ml/kg, 36% of blood volume). All rats survived for 4hr after the infusion of HbV; hemodynamic and respiratory functions were preserved, indicating that the flocculation does not induce capillary embolism. Blood exchange with rHSA and subsequent infusion of HbV showed more stable systemic parameters because of the longer retention of rHSA in blood than other plasma substitutes, indicating that rHSA is suitable for combination with HbV in this experimental model.

    KW - Artificial red cells

    KW - Biomacromolecules

    KW - Blood substitutes

    KW - Hemoglobin

    KW - Liposome

    UR - http://www.scopus.com/inward/record.url?scp=79960847589&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=79960847589&partnerID=8YFLogxK

    U2 - 10.1002/pat.1964

    DO - 10.1002/pat.1964

    M3 - Article

    AN - SCOPUS:79960847589

    VL - 22

    SP - 1216

    EP - 1222

    JO - Polymers for Advanced Technologies

    JF - Polymers for Advanced Technologies

    SN - 1042-7147

    IS - 8

    ER -